MARKET

SGEN

SGEN

Seattle Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

114.75
+1.46
+1.29%
After Hours: 114.50 -0.25 -0.22% 17:13 11/15 EST
OPEN
113.96
PREV CLOSE
113.29
HIGH
114.81
LOW
113.05
VOLUME
952.87K
TURNOVER
--
52 WEEK HIGH
114.81
52 WEEK LOW
51.50
MARKET CAP
19.67B
P/E (TTM)
-61.4195
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SGEN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SGEN News

  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.2d ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.3d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About SGEN

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
More

Webull offers Seattle Genetics, Inc. (SGEN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.